Additive Effects of Genetic Variation in GCK and G6PC2 on Insulin Secretion and Fasting Glucose by Li, Xia et al.
Additive Effects of Genetic Variation in GCK and G6PC2
on Insulin Secretion and Fasting Glucose
Xia Li,
1 Yu-Hsiang Shu,
1 Anny H. Xiang,
1 Enrique Trigo,
2 Johanna Kuusisto,
3 Jaana Hartiala,
1,4
Amy J. Swift,
5 Miwa Kawakubo,
1 Heather M. Stringham,
6 Lori L. Bonnycastle,
5 Jean M. Lawrence,
7
Markku Laakso,
3 Hooman Allayee,
1,4 Thomas A. Buchanan,
2,8 and Richard M. Watanabe
1,8
OBJECTIVE—Glucokinase (GCK) and glucose-6-phosphatase
catalytic subunit 2 (G6PC2) regulate the glucose-cycling step in
pancreatic -cells and may regulate insulin secretion. GCK
rs1799884 and G6PC2 rs560887 have been independently associ-
ated with fasting glucose, but their interaction on glucose-insulin
relationships is not well characterized.
RESEARCH DESIGN AND METHODS—We tested whether
these variants are associated with diabetes-related quantitative
traits in Mexican Americans from the BetaGene Study and
attempted to replicate our ﬁndings in Finnish men from the
METabolic Syndrome in Men (METSIM) Study.
RESULTS—rs1799884 was not associated with any quantitative
trait (corrected P  0.1), whereas rs560887 was signiﬁcantly
associated with the oral glucose tolerance test 30-min incremen-
tal insulin response (30 insulin, corrected P  0.021). We found
no association between quantitative traits and the multiplicative
interaction between rs1799884 and rs560887 (P  0.26). How-
ever, the additive effect of these single nucleotide polymor-
phisms was associated with fasting glucose (corrected P  0.03)
and 30 insulin (corrected P  0.027). This additive association
was replicated in METSIM (fasting glucose, P  3.5  10
10 30
insulin, P  0.028). When we examined the relationship be-
tween fasting glucose and 30 insulin stratiﬁed by GCK and
G6PC2, we noted divergent changes in these quantitative traits
for GCK but parallel changes for G6PC2. We observed a similar
pattern in METSIM.
CONCLUSIONS—Our data suggest that variation in GCK and
G6PC2 have additive effects on both fasting glucose and insulin
secretion. Diabetes 58:2946–2953, 2009
G
enome-wide association (GWA) studies have
identiﬁed several loci for type 2 diabetes (1–5)
and type 2 diabetes–related quantitative traits
(6–20). Two of these loci, glucokinase (GCK)
(21–23) and glucose-6-phosphatase catalytic subunit 2
(G6PC2) (9,10), regulate the critical glucose-sensing
mechanism within pancreatic -cells. Mutations in GCK
confer susceptibility to maturity-onset diabetes of the
young (MODY)-2 (24–26), and a 30 GCK promoter
variant (rs1799884) has been shown to be associated with
-cell function (21), fasting glucose, and birth weight (23).
Chen et al. (9) demonstrated an association between the
G6PC2 region and fasting glucose, an observation repli-
cated by Bouatia-Naji et al. (10). Although fasting glucose
levels are associated with both GCK and G6PC2, there has
been no evidence that genetic variation at these two loci
contribute a risk for type 2 diabetes, suggesting contribu-
tion to mild elevations in glycemia.
GCK phosphorylates glucose to glucose-6-phosphate,
whereas G6PC2 dephosphorylates glucose-6-phosphate
back to glucose, forming a glucose cycle previously dem-
onstrated to exist within pancreatic -cells (27,28). The
important role of GCK in glucose sensing by pancreatic
islets has been demonstrated by numerous studies, and
other studies suggest a role for glucose cycling in insulin
secretion and diabetes (28–30), implying that the balance
between GCK and G6PC2 activity is important for deter-
mining glycolytic ﬂux, ATP production, and subsequent
insulin secretion. This was validated by a demonstration
that direct manipulation of glucose cycling alters insulin
secretion (31,32).
BetaGene is a study in which we are performing
detailed phenotyping of Mexican American probands
with recent gestational diabetes mellitus (GDM) and
their family members to obtain quantitative estimates of
body composition, insulin sensitivity (SI), acute insulin
response (AIR), and -cell compensation (disposition
index) with the goal of identifying genes inﬂuencing
variations in type 2 diabetes–related quantitative traits
(33–35). Based on the evidence that variation in GCK
(rs1799884) and G6PC2 (rs560887) are independently
associated with fasting glucose concentrations and both
are crucial to glucose cycling in -cells, we hypothe-
sized that interaction between these loci may be asso-
ciated not just with fasting glucose but also with
measures of insulin secretion or -cell function. We
tested this hypothesis in the BetaGene Study and, for
replication, in a separate sample of Finnish men partic-
ipating in the METabolic Syndrome in Men (METSIM)
Study (36).
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The BetaGene Study
Subject recruitment. Subject recruitment for BetaGene was ongoing at the
time of these analyses. Subjects are Mexican American (both parents and 3
grandparents Mexican or of Mexican descent) who are either probands with
GDM diagnosed within the previous 5 years and diagnosed in their family
members or non-GDM probands with normal glucose levels in pregnancy in
the past 5 years. Subject recruitment has been previously detailed (33–35).
The institutional review boards of participating institutions approved all
protocols for BetaGene, and all participants provided written informed
consent before participation.
Clinical protocols. Phenotyping was performed on two separate visits to the
University of Southern California General Clinical Research Center. The ﬁrst
visit consisted of a physical examination, DNA collection, and an oral glucose
tolerance test (OGTT; 75 g) as previously described (33–35). Participants with
fasting glucose 126 mg/dl were invited back for a second visit, which
consisted of a dual-energy X-ray absorptiometry scan for body composition
(percent of body fat) and an insulin-modiﬁed intravenous glucose tolerance
test (IVGTT) performed as previously described (37).
Assays. Plasma glucose is measured on an autoanalyzer using the glucose
oxidase method (YSI Model 2300; Yellow Springs Instruments, Yellow Springs,
OH). Insulin is measured by two-site immunoenzymometric assay that has
0.1% crossreactivity with proinsulin and intermediate split products.
The METSIM Study
Subject recruitment. We attempted to replicate our ﬁndings in subjects
participating in the ongoing METSIM Study (36). The primary goal of the
METSIM Study was to investigate the effect of genetic variation on risk for
type 2 diabetes and cardiovascular disease in a random sample of Finnish men
(aged 50–70 years) living in the town of Kuopio, eastern Finland (population
95,000). There were 5,327 men from this ongoing population-based study
included in this report. The ethics committee of the University of Kuopio and
in accordance with the Helsinki Declaration approved the METSIM Study.
Clinical protocols. Phenotyping for METSIM was performed in a single visit
to the Clinical Research Unit of the University of Kuopio. In addition to fasting
blood samples for DNA, glucose, and insulin, all subjects underwent an OGTT
with samples obtained at 30 and 120 min postload.
Molecular analysis. In BetaGene, GKC 30G3A polymorphism
(rs1799884) and G6PC2 rs560887 were genotyped using the TaqMan system
(Applied Biosystems) (38,39). Genotyping discrepancy rate based on blinded
duplicates was 0.1%, and overall genotyping success rates were 97% for
rs1799884 and 99% for rs560887.
In METSIM, GCK rs4607517 and G6PC2 rs560887 were genotyped by the
homogeneous MassEXTEND reaction using the MassARRAY System (Seque-
nom) (9). In the HapMap CEU data (40), which provide a good representation
of linkage disequilibrium in Finns (41), rs4607517 is a perfect proxy for
rs1799884 (D’  1.0, r
2  1.0). There were no genotype discrepancies based on
220 blinded duplicates, and overall genotyping success rates were 96% for
rs4607517 and 94% for rs560887.
Data analysis. Genotype data were tested for deviation from Hardy-
Weinberg equilibrium and for non-Mendelian inheritance using PEDSTATS
version 0.6.4 (42). Allele frequencies for BetaGene samples were estimated
using all available data taking into account relatedness using SOLAR version
2.1.4 (43,44), whereas METSIM frequencies were estimated by gene counting.
We calculated two measures of insulin response to glucose: the difference
between the 30 and fasting plasma insulin concentration from OGTT (30
Insulin) and the incremental area under the insulin curve for the ﬁrst 10 min
of the IVGTT (AIR). IVGTT glucose and insulin data were analyzed using the
minimal model (MINMOD Millennium version 5.18) to derive measures of
glucose effectiveness and SI (45). Disposition index, a measure of -cell
compensation for insulin resistance, was computed as the product of SI and
AIR. We also computed an OGTT-derived measure of -cell compensation as
the product of SI and 30 insulin (DI30).
We initially examined the association between the two single nucleotide
polymorphisms (SNPs) and fasting glucose, fasting insulin, 30 insulin, and
AIR given our primary hypothesis that these variants may underlie variation in
these speciﬁc quantitative traits. Details of the association analyses are
described below. We recognized that these variants could also underlie
variation in other type 2 diabetes–related quantitative traits. We tested these
SNPs for association with 2-h glucose, 2-h insulin, SI,S G, BMI, and percent of
body fat as a series of secondary analyses.
Quantitative trait data were statistically transformed to approximate
univariate normality before analyses. We ﬁrst tested each SNP for association
with type 2 diabetes–related quantitative traits using likelihood ratio testing
under a variance components framework as implemented in SOLAR (43,44).
Because families were ascertained through probands based on previous GDM
status, we corrected for ascertainment bias by conditioning each model on the
proband’s phenotype. Each SNP was tested for association with quantitative
traits assuming a dominant genetic model because of the relatively low minor
allele frequencies observed for both SNPs. All models were adjusted for age,
sex, and, where appropriate, percent body fat. P values were corrected for
multiple testing to account for the number of traits tested (four traits in the
primary analysis, six traits in the secondary analysis). We used PACT to control
for the number of tests performed and to account for the correlation among
the quantitative traits tested for association (46). PACT compares the observed
test statistic with their asymptotic distribution using numeric integration and
directly accounts for correlation among both dependent and independent
variables.
Next, we performed a test of the association between type 2 diabetes–
related quantitative traits and the interaction between GCK and G6PC2.W e
compared a model with age, sex, rs1799884, and rs560887 as main effects with
a second model that included the multiplicative interaction between the two
SNPs. As in the univariate analyses, we assumed dominant genetic models for
both SNPs. We tested for a signiﬁcant interaction effect using a 1-d.f. test and
performed a Bonferroni correction to account for the number of traits tested
because PACT is not valid for multi-d.f. tests (46). However, because many of
the quantitative traits examined are correlated and Bonferroni assumes
independence, the corrected P values we report should be overly
conservative.
Given that GCK and G6PC2 work in opposite directions on the glucose
cycle, we hypothesized that additivity may best characterize their interaction.
Therefore, we performed a second analysis in which we used a 2-d.f. test to
test the joint effect of rs1799884 and rs560887 for association with type 2
diabetes–related quantitative traits.
METSIM Study. Speciﬁc results observed in the BetaGene Study were tested
in the METSIM samples. Standard regression methods were used to test for
association between genetic variants and type 2 diabetes–related traits as
METSIM participants are unrelated individuals. Covariates included age and,
when appropriate, BMI. Given that only speciﬁc a priori hypotheses were
tested in the METSIM data, we did not apply a correction for multiple testing.
All data for BetaGene are reported as age- and sex-adjusted means and SD,
whereas METSIM data are reported as age-adjusted means and SD unless
noted otherwise.
RESULTS
The BetaGene Study. We report results from 861 Beta-
Gene individuals in 251 families with available phenotype
and genotype data (Table 1). Probands, siblings, and
cousins were similar in median age, BMI, and percent of
body fat, although these characteristics tended to be
highest in the GDM probands and lowest in cousins.
Non-GDM probands were slightly younger and less obese
compared with GDM probands, reﬂecting the fact that
BetaGene participant accrual was ongoing and recruit-
ment of non-GDM probands was slightly lagging to allow
for matching as previously described (33–35). Parameters
of glucose metabolism tended to be best in the non-GDM
probands and worst in the GDM probands.
GCK rs1799884 (GA) had a minor allele frequency of
18.0% and was marginally associated with fasting glucose
(Table 2, P  0.052) that modestly increased (P  0.021)
after adjustment for body fat. Individuals homozygous for
the G allele had a lower average fasting glucose compared
with those with at least one A allele (5.13 	 0.52 vs. 5.22 	
0.59 mmol/l). However, the association between GCK
rs1799884 and fasting glucose did not remain signiﬁcant
when corrected for multiple testing. In addition, we did
not observe any evidence for association between this
SNP and measures of insulin secretion (Table 2) or other
type 2 diabetes–related quantitative traits (Table 3), al-
though there was a tendency for mean fasting insulin, 30
insulin, and AIR to be lower in individuals with at least
one rs1799884 A allele (Table 2).
G6PC2 rs560887 (GA) had a minor allele frequency of
14.5% and was nominally associated with fasting glucose
(Table 2, P  0.015) and 30 insulin (P  0.0038) and
marginally associated with AIR (P  0.088). These associ-
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model (P  0.059, P  0.014, and P  0.222, respectively).
Individuals homozygous for the rs560887 G allele had an
average fasting glucose higher than those with at least one
A allele (5.19 	 0.52 vs. 5.08 	 0.61 mmol/l). In parallel
with these glucose differences, both 30 insulin and AIR
were, on average, higher in individuals homozygous for the
G allele (Table 2). Only the association with 30 insulin
remained signiﬁcant after correction for multiple testing
(PACT  0.021). Although G6PC2 rs560887 was not asso-
ciated with most type 2 diabetes–related quantitative
traits, we did observe an association between this SNP and
percent body fat (PACT  0.035), where individuals ho-
mozygous for the G allele had higher trait values (Table 3).
We found no evidence for association between the
multiplicative interaction between GCK rs1799884 and
G6PC2 rs560887 and type 2 diabetes–related quantitative
traits (uncorrected P  0.26), and additional adjustment
for body fat did not change the overall results. In contrast,
when we tested whether the additive effects of GCK
rs1799884 and G6CP2 rs560887 were associated with type
2 diabetes–related quantitative traits, we observed associ-
ation with fasting glucose (Bonferroni P  0.03) and 30
insulin (Bonferroni P  0.027).
Bouatia-Naji et al. reported a linear relationship be-
tween number of “glucose-lowering alleles” for GCK,
G6PC2, and GCKR and fasting glucose, which suggested
additive effects of these alleles on fasting glucose (10). We
observed a similar linear relationship (data not shown)
when we stratiﬁed GCK and G6PC2 genotypes, consistent
with the results of our statistical analysis and the obser-
vations of Bouatia-Naji et al. (10). However, given the
speciﬁcity of these two gene products in regulating the
glucose-sensing step in pancreatic -cells, we hypothe-
sized the primary effect of variation in GCK and G6PC2 to
be at the level of insulin secretion, not directly upon
glucose. We tested this hypothesis using the conceptual
construct depicted in Fig. 1. The presence of an A allele in
the GCK rs1799884 promoter variant is hypothesized to
reduce GCK gene expression and result in decreased GCK
protein (23). This should result in modest reductions in
glycolytic ﬂux and ATP production, resulting in modest
reductions in insulin secretion for any level of circulating
glucose. G6PC2 rs560887 is located in intron 3, just 26 bp
proximal to exon 4 (9,10). The presence of an A allele may
result in a G6PC2 isoform with differential activity that
favors increased conversion of glucose-6-phosphate to
glucose, signiﬁcantly reducing glycolytic ﬂux and ATP
generation, resulting in larger reductions in insulin secre-
tion for any glucose level. The balance between the effects
of GCK and G6PC2 should differentially modulate insulin
secretion, depending upon genotype combination as de-
tailed in Fig. 1.
When we stratiﬁed individuals by GCK and G6PC2
genotypes as depicted in Fig. 1, a linear trend in 30
insulin (Fig. 2, top; P  0.0016) is observed where on
average, 30 insulin decreased 
5.6 pmol/l among geno-
type groups. We do not see a clear linear relationship
when the same stratiﬁcation is used to examine the
relationship with fasting glucose (Fig. 2, bottom; P 
0.191). Thus, the linearity between GCK and G6PC2 geno-
type combinations and insulin secretion does not directly
translate into linear changes in fasting glucose. We ob-
served a similar dichotomy when we examined fasting
TABLE 1
Subject characteristics
GDM
probands Siblings Cousins
Non-GDM
probands
Men/women 164/0 239/154 133/101 67/0
Age (years) 35.5 (5.6) 35.1 (8.6) 33.2 (9.3) 34.6 (4.9)
BMI (kg/m
2) 38.8 (5.5) 32.8 (8.4) 31.0 (8.5) 36.9 (5.7)
Body fat (%) 31.4 (6.7) 29.8 (5.9) 28.4 (6.4) 28.9 (6.0)
Fasting glucose (mM) 5.3 (0.6) 5.2 (0.5) 5.1 (0.6) 4.8 (0.4)
2-h glucose (mM) 8.6 (2.4) 7.7 (2.2) 6.9 (2.0) 6.3 (1.2)
Fasting insulin (pM) 74 (53) 62 (47) 59 (52) 49 (37)
30 insulin (pM) 494 (316) 522 (342) 547 (373) 506 (353)
2-h insulin (pM) 647 (475) 523 (410) 453 (380) 362 (252)
30 insulin (pM) 420 (288) 461 (320) 488 (345) 458 (325)
SG (10
2 min
1) 1.58 (0.55) 1.73 (0.68) 1.83 (0.71) 2.01 (0.69)
SI (10
3 min
1 per pM) 2.98 (1.77) 2.95 (1.64) 3.14 (1.72) 3.32 (1.46)
AIR (pM  10 min) 4,540 (4,280) 5,771 (5,565) 6,313 (5,690) 7,082 (5,079)
Disposition index 10,933 (8,882) 14,002 (9,519) 15,518 (9,712) 19,173 (9,267)
Data are unadjusted median (interquartile range).
TABLE 2
Univariate tests of associations between genetic variants and fasting glucose and measures of insulin secretion
GCK (rs1799884) G6PC2 (rs560887)
GG
(n  405)
GA or AA
(n  207)
Uncorrected
P*
GG
(n  458)
GA or AA
(n  165)
Uncorrected
P*
Fasting glucose (mM) 5.13 	 0.52 5.22 	 0.59 0.052 5.19 	 0.52 5.08 	 0.61 0.015
Fasting insulin (pM) 63.2 	 49.7 57.5 	 47.3 0.412 60.5 	 45.3 63.0 	 57.0 0.833
30 insulin (pM) 489 	 338 447 	 314 0.119 488 	 339 427 	 300 0.004
AIR (pM  10 min) 6,197 	 6,238 5,721 	 4,258 0.770 6,196 	 5,673 5,650 	 5,485 0.088
Data are unadjusted means 	 SD unless otherwise indicated. *Age- and sex-adjusted P value not corrected for multiple testing.
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glucose-raising alleles, as previously performed by Boua-
tia-Naji et al. (10); fasting glucose is linear with total
number of glucose-raising alleles, whereas 30 insulin is
not (data not shown).
Grouping and ordering by genotype as described above
is semi-artiﬁcial. Therefore, we plotted fasting glucose
against 30 insulin from BetaGene stratiﬁed by GCK and
G6PC2 genotypes (Fig. 3, top) to better characterize the
relationship between 30 insulin and fasting glucose. We
noted a different pattern of coordinate changes in fasting
glucose and 30 insulin associated with variation in GCK
as compared with variation in G6PC2. For GCK rs1799884,
individuals homozygous for the G allele (Fig. 3, circles)
had lower fasting glucose and higher 30 insulin than
individuals with at least one A allele (Fig. 3, squares). For
G6PC2 rs560887, individuals homozygous for the G allele
(Fig. 3, open symbols) had higher fasting glucose and
higher 30 insulin than individuals with at least one A
allele (Fig. 3, solid symbols). In other words, variation in
GCK led to inverse changes in fasting glucose and 30
insulin, whereas variation in G6PC2 led to parallel
changes in these two traits.
Replication in the METSIM Study. Given the observa-
tion of additivity between GCK rs1799884 and G6PC2
rs560887 on fasting glucose and 30 insulin in BetaGene,
we attempted to replicate these ﬁndings in the METSIM
sample, in which GCK rs4607517 is in perfect linkage
disequilibrium with rs1799884. GCK rs4607517 was asso-
ciated with fasting glucose but not associated with 30
insulin (Table 4). G6PC2 rs560887 was associated with
fasting glucose and marginally associated with 30 insu-
lin (Table 4). The multiplicative interaction between GCK
rs4607517 and G6PC2 rs560887 was weakly associated
with fasting glucose (P  0.038) and marginally associated
with 30 insulin (P  0.049). However, the 2-d.f. test of
the joint additive effect of the two SNPs was signiﬁcant for
both fasting glucose (P  3.5  10
10) and 30 insulin
(P  0.028). The evidence for association between the
joint additive effect of both SNPs and fasting glucose was
not affected when BMI was included as an additional
covariate (P  3.3  10
11); the association with 30
insulin became stronger when BMI was included as a
G/G
G/G
G/A or A/A
G/A or A/A
Glucokinase (GCK)
Glucose-6-phosphatase,
Catalytic Subunit 2 (G6PC2)
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FIG. 1. Hypothesized effect of GCK rs1799884 and G6PC2 rs560887
genotype combinations on ATP production and insulin secretion in
pancreatic -cells. Upper portion of the ﬁgure shows the glucose-
cycling step and the effect of speciﬁc alleles in GCK and G6PC2 on
activity of each enzyme: thick arrow depicts increased activity, thin
arrow depicts reduced activity. Lower portion shows the speciﬁc
genotype combinations and the hypothesized effect on ATP production
and subsequent insulin secretion.
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FIG. 2. The 30 insulin and fasting glucose stratiﬁed by GCK
rs1799884 and G6PC2 rs560887 genotypes. A: Age- and sex-adjusted
30 insulin (means  SE) stratiﬁed by GCK rs1799884 and G6PC2
rs560887 genotype combination. Genotype groups are ordered by
hypothesized effect on glucose cycling in the pancreatic -cell (see text
for details). Dominant genetic models are assumed for both loci. 30
insulin changed linearly (P  0.0016) with genotype group. B: Age-
and sex-adjusted fasting plasma glucose (means  SE) stratiﬁed by
genotype. Details are as described for top panel. Fasting glucose was
not linearly related to genotype group (P  0.191).
TABLE 3
Univariate tests of associations between genetic variants and additional type 2 diabetes–related quantitative traits
GCK (rs1799884) G6PC2 (rs560887)
GG
(n  405)
GA or AA
(n  207)
Uncorrected
P*
GG
(n  458)
GA or AA
(n  165)
Uncorrected
P*
BMI (kg/m
2) 29.6 	 6.4 28.7 	 5.6 0.150 29.7 	 6.2 28.3 	 5.7 0.012
Body fat (%) 32.2 	 8.6 31.8 	 8.3 0.121 32.5 	 8.5 31.4 	 8.4 0.007
2-h glucose (mM) 7.39 	 2.24 7.40 	 2.07 0.477 7.38 	 2.08 7.45 	 2.43 0.805
2-h insulin (pM) 505 	 416 485 	 374 0.764 502 	 409 488 	 377 0.871
SG (10
2 min
1) 1.78 	 0.71 1.73 	 0.66 0.340 1.78 	 0.67 1.73 	 0.74 0.218
SI (10
3 min
1 per pM) 3.02 	 1.78 3.00 	 1.48 0.944 2.96 	 1.68 3.12 	 1.66 0.469
Data are unadjusted means 	 SD unless otherwise indicated. *Age- and sex-adjusted P value not corrected for multiple testing.
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ship between fasting glucose and 30 insulin stratiﬁed by
GCK rs4607517 and G6PC2 rs560887 genotype groupings,
an identical pattern of relationship to that seen in Bet-
aGene was observed (Fig. 3, bottom). For GCK rs4607517,
individuals homozygous for the G allele had lower fasting
glucose and higher 30 insulin than individuals with at
least one A allele. For G6PC2 rs560887, individuals ho-
mozygous for the G allele had higher fasting glucose and
higher 30 insulin than individuals with at least one A
allele.
DISCUSSION
Our results from Mexican Americans, replicated in a
sample of Finnish men, show that variation in both GCK
and G6PC2 have additive effects on both fasting glucose
and insulin secretion. Our examination of the relationship
between 30 insulin and fasting glucose stratiﬁed by GCK
and G6PC2 genotype reveals that the joint effect of genetic
variation in these two genes may be through distinct
mechanisms. Variation in GCK leads to inverse changes in
fasting glucose and insulin secretion, consistent with a
primary effect on insulin secretion. Variation in G6PC2
leads to parallel changes in fasting glucose and insulin
secretion, suggesting a primary effect on glucose, with
secondary changes in insulin secretion.
Table 5 summarizes our examination of the effects of
GCK rs1799884 and G6PC2 rs560887 on fasting glucose
and 30 insulin. Although it is possible that our conclu-
sion of these variants having an additive effect could be
driven mainly by G6PC2 rs560887, the summary in Table 5
suggests otherwise. It is clear that in both BetaGene and
METSIM, the model testing the joint effect of GCK and
G6PC2 shows greater signiﬁcance than the effect of each
individual gene variant alone, which suggests both genes
are contributing to the effect on fasting glucose and 30
insulin. In support of this observation, when we tested
for the additional effect of GCK in the presence of G6PC2
we observed marginal or signiﬁcant effects for fasting
glucose (P  0.058 for BetaGene; P  0.0009 for METSIM)
and 30 insulin (P  0.148 for BetaGene; P  0.723 for
METSIM). Our a priori hypothesis tested whether the
multiplicative interaction between rs1799884 and rs560887
was associated with type 2 diabetes–related quantitative
traits. In BetaGene we observed no evidence for a multi-
plicative interaction; our analysis favored a joint additive
effect of these two loci. However, our relatively small size
may limit our ability to exclude a multiplicative interac-
tion. A priori power estimates indicated that a sample size
of 600 should have provided 80% power to detect a
multiplicative interaction effect that accounted for 
1.8%
of the variability in fasting glucose or 30 insulin, assum-
ing 0.01, minor allele frequencies of 15% for both loci,
and dominant genetic models for both loci. Thus, Beta-
Gene cannot discount the possibility that a very weak
multiplicative interaction exists between these two loci. In
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FIG. 3. The 30 insulin vs. fasting plasma glucose stratiﬁed by GCK
rs1799884 and G6PC2 rs560887 genotype. A: Shows results from the
BetaGene Study. Model-predicted age- and sex-adjusted 30 insulin
(means  SD) stratiﬁed by genotype is plotted against model-
predicted age- and sex-adjusted fasting plasma glucose (means  SD).
Solid symbols represent G6PC2 rs560887 G/A or A/A genotypes and
open symbols represent G6PC2 rs560887 G/G genotype. Circles repre-
sent GCK rs1799884 G/G genotype and squares represent GCK
rs1799884 G/A and A/A genotypes. B: Shows results from the METSIM
Study. Details are identical to that described for the top panel except
that circles and squares represent GCK rs4607517 genotypes.
TABLE 4
Univariate tests of associations between genetic variants and fasting glucose and 30 insulin in METSIM
GCK (rs4607517) G6PC2 (rs560887)
GG
(n  4,185)
GA or AA
(n  962) P*
GG
(n  2,661)
GA or AA
(n  2,315) P*
Fasting glucose (mM) 5.68 	 0.49 5.74 	 0.50 0.0003 5.72 	 0.49 5.64 	 0.50 1.2  10
8
30 insulin (pM) 343 	 270 333 	 235 0.7362 351 	 280 332 	 244 0.0517
Data are unadjusted means 	 SD unless otherwise indicated. *Age-adjusted P value.
TABLE 5
Summary of modeling analysis
Model
BetaGene METSIM
Fasting
glucose
30’
insulin
Fasting
glucose
30’
insulin
Age  sex  GCK 0.058 0.148 0.0003 0.736
Age  sex  G6PC2 0.012 0.012 1.2  10
8 0.052
Age  sex  GCK 
G6PC2  GCK 
G6PC2 0.257 0.396 0.038 0.049
Age  sex  GCK 
G6PC2 0.0075 0.0067 3.5  10
10 0.028
Data are uncorrected P values for the genetic effect being tested.
Underline indicates the genetic effect being tested.
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6 times larger than
BetaGene, showed modest evidence for a multiplicative
interaction (Table 5) suggesting that a weak multiplicative
interaction between GCK and G6PC2 could be contribut-
ing to variation in fasting glucose and 30 insulin. This
interaction would need to be replicated in a sample of
similar or larger size.
Our initial examination of the additive effect of these
two genes was motivated by the fact that when we plotted
30 insulin against GCK rs1799884 and G6PC2 rs560887
genotype combinations sorted by the hypothesized bio-
logic effect on insulin secretion, we observed a linear
relationship with 30 insulin. Recently, Pirot et al. (47)
showed in mouse and human islets that G6PC2 protein
levels and enzymatic activity increased when islets were
incubated in high-glucose media, whereas those for GCK
did not change, suggesting that G6PC2 activity may adapt
to changes in glucose to alter insulin secretion. Because
insulin secretion was not measured, it is unclear whether
the changes observed translated into altered rates of
insulin secretion. However, previous studies have demon-
strated that manipulation of glucose cycling in insulin-
secreting cell lines does result in changes in insulin
secretion (31,32). For example, Iizuka et al. (32) showed
that altering glucose cycling by varying the G6PC2-to-GCK
ratio leads to reductions in ATP production and reduced
glucose-stimulated insulin secretion in MIN-6 cells. Taken
together, these studies examining the balance between
GCK and G6PC2 support our hypothesized effects of
variation in GCK and G6PC2 on insulin secretion (com-
pared with Fig. 1). However, they do not account for the
differences we observed in the relationship between fast-
ing glucose and insulin secretion when stratiﬁed by these
two loci.
Primary enhancement of -cell sensitivity to glucose
should result in increased systemic insulin concentrations
in relation to glucose levels. The fact that the linearity in
30 insulin we observed between GCK rs1799884 and
G6PC2 rs560887 genotype combinations did not extend to
fasting glucose (compared with Fig. 2) is unexpected. We
conﬁrmed this initial observation by examining the rela-
tionship between fasting glucose and 30 insulin, strati-
fying on GCK and G6PC2 genotype (compared with Fig.
3). In both the BetaGene and METSIM studies, the pres-
ence of the GCK rs1799884 A allele resulted in lower 30
insulin and higher fasting glucose, regardless of G6PC2
genotype. The results suggest that variation in GCK may
alter insulin secretion and fasting glucose in the tradition-
ally envisioned manner where changes in insulin secretion
result in reciprocal changes in glucose concentration.
However, the presence of a G6PC2 A allele resulted in
both lower 30 insulin and fasting glucose, regardless of
GCK genotype. There are two possible mechanisms that
may explain our observation. First, variation in G6PC2
could have a direct and independent effect to regulate
hepatic glucose production. This effect is unlikely because
the hepatic isoform of glucose-6-phosphatase is encoded
by an independent gene. Second, variation in G6PC2 could
alter a characteristic of insulin secretion that disrupts the
normal signaling between the pancreas and other tissues,
resulting in both insulin secretion and glucose changing in
tandem. Recent studies by Matveyenko et al. (48,49)
provide evidence for this possibility. Speciﬁcally, their
studies show that in canines with partial pancreas resec-
tion or in rats transgenic for human islet amyloid polypep-
tide, disruption of pulsatile insulin secretion results in
hepatic insulin resistance and impaired fasting glucose (A.
Matveyenko, personal communication). They conclude
that the loss of pulsatile insulin secretion results in a loss
of efﬁciency in insulin action at the liver, leading to hepatic
insulin resistance and increased glucose output, which
subsequently leads to a gradual rise in glucose levels.
Variation in G6PC2 may disrupt pulsatility in insulin
secretion, thereby reducing insulin-signaling efﬁciency be-
tween the pancreas and liver. The small increase in
glucose because of hepatic insulin resistance may result in
modest increases in absolute insulin secretion. Additional
studies will be required to test this hypothesis.
Finally, we observed association between G6PC2
rs560887 and measures of adiposity that have not been
previously reported. BMI and body fat were both lower in
the presence of the A allele (compared with Table 3), but
the biologic mechanism underlying this association is
unclear. One possibility is that if variation in G6PC2
results in decreased insulin-signaling efﬁciency because of
the loss of pulsatility and leads to hepatic insulin resis-
tance, then a similar loss of insulin signaling may occur in
other tissues, such as adipose. Our observed association
between variation in G6PC2 and adiposity will require
replication in other populations and further study to
elucidate the mechanism underlying the association.
In conclusion, we observed evidence for an additive
effect of variation in GCK (rs1799884) and G6PC2
(rs560887) on insulin secretion and fasting glucose. When
stratiﬁed by genotype, the effect of GCK rs1799884 follows
an expected pattern of reduced insulin secretion and
reciprocal increase in fasting glucose. By contrast, glucose
levels and insulin secretion change in parallel with G6PC2
rs560887, suggesting a primary effect on insulin signaling
to regulate hepatic glucose production. Our analyses high-
light the importance of considering biologic effects in
assessing relationships between genotype and quantitative
traits. Like previous studies, our analyses show that these
variants account for only a small fraction of the variability
in insulin secretion or glucose. The remaining variability is
likely because of the effects of other common genetic
variants of both modest and moderate effect and a variety
of additional gene-gene and gene-environment interac-
tions. Thus, additional studies of samples with detailed
phenotyping will be necessary to fully unravel the genetic
architecture underlying glucose regulation and diabetes.
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